WO2008126980A1 - Pharmaceutical composition for wound healing containing anthocyanin extracted from the black soybean seed coat - Google Patents
Pharmaceutical composition for wound healing containing anthocyanin extracted from the black soybean seed coat Download PDFInfo
- Publication number
- WO2008126980A1 WO2008126980A1 PCT/KR2008/000513 KR2008000513W WO2008126980A1 WO 2008126980 A1 WO2008126980 A1 WO 2008126980A1 KR 2008000513 W KR2008000513 W KR 2008000513W WO 2008126980 A1 WO2008126980 A1 WO 2008126980A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- anthocyanin
- glucoside
- wound healing
- wound
- soybean seed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Definitions
- composition for wound healing containing anthocyanin extracted from the black soybean seed coat
- the present invention relates to pharmaceutical compositions for wound healing, containing anthocyanin as an active ingredient, which is extracted from black soybeans, especially black soybean seed coats. More specifically, the anthocyanin is composed of cyanidin-3-glucoside, delphinidin- 3-glucoside, and petunidin-3-glucoside.
- Anthocyanin is a water-soluble pigment glucoside, which exists in flowers, fruits, stems, leaves, and roots of plants. It is usually found in vacuoles of plants and it is a natural dye representing colors such as violet, red, and blue according to the acidity of cell sap, the chemical structure of dye compounds, and binding status with other metal ions.
- Anthocyanin is composed of aglycone and glycoside. Currently the anthocyanin component is extracted from such plants as grapes, strawberries, olives, red cabbages, eggplants, roses, etc. and used as various materials. Yet, in fact, it is extracted and used almost as a co-pigment and often used with the compounds of other ingredients.
- Anthocyanin a natural vegetable dye, has recently been known to have some bioactivities .
- the well-known examples are anti-aging and antibacterial effect, anti-mutagenicity, cholesterol decrease, eyesight improvement, blood vessel protection, anti-ulcerative, and antioxidant effect. These bioactivities are basic for every kind of anthocyanin, but it was recently found that each anthocyanin has slightly different bioactivities.
- a wound means an injured part of a body, including pathologically cut or damaged tissues in internal or external surface such as muscles, nervous tissues, bones, soft tissues, internal organs, and vascular tissues.
- the examples are contusion, noncurative traumatic wound, tissue destruction by irradiation, abrasion, osteonecrosis, laceration, avulsion, penetrated wound, gun shot wound, incised wound, burn, frostbite, skin ulcer, xeroderma, palmoplantar keratoderma, rough and cracked skin, dermatitis, pain from dermatophytosis, operation wound, vascular disorder wound, cornea wound, decubitus ulcer, bedsore, diabetic and poor circulation related state such as diabetic skin erosion, chronic ulcer, stitched part after plastic surgery, spinal cord injury wound, gynaecological wound, chemical wound, and acne.
- the examples are not restricted by these and they also include some partial injuries .
- black soybeans contain essential fatty acids, lecithin, fiber, saponin, etc., so that they have the effect to prevent and treat adult diseases such as hypertension, diabetes, arteriosclerosis, and obesity.
- the vegetable fiber contained in black soybeans is known to have the effect to prevent not only constipation but also colon cancer.
- Donguibogam the Korean medical book written in the 17 th century, describes black soybeans as "a drug that protects the five viscera, keeps intestines warm by helping twelve meridians, gets rid of boils, and treats radiating pain".
- anthocyanin a pigment contained in black soybeans, has the anti-aging effect in case of a constant use as antioxidants.
- Isoflavone the soy protein, contains saponin and phytosterol as well as genistin that have powerful anticancer activities, and helps calcium absorption into bones.
- the seed coats of black soybeans contain an anticancer material called glycitein.
- Anthocyanin is a water-soluble pigment glucoside and largely divided into six kinds of anthocyanidins depending on the number of the hydroxyl groups and the methylation of specific hydroxyl groups. It is also divided into hundreds of kinds depending on the sort of sugar, which is bonded with anthocyanidins, and the sort and bonding location of the acyl group.
- the object of the present invention is to provide the pharmaceutical compositions containing anthocyanin extracted from black soybean seed coats to treat wounds.
- the present invention relates to pharmaceutical compositions for wound healing, containing anthocyanin as an active ingredient, which is extracted from black soybeans, especially black soybean seed coats. More specifically, the anthocyanin is composed of cyanidin-3-glucoside, delphinidin- 3-glucoside, and petunidin-3-glucoside .
- the purified anthocyanin of the present invention is composed of 65-80 weight% of cyanidin-3-glucoside, 15-25 weight% of delphinidin-3-glucoside, and 5-10 weight% of petunidin-3-glucoside.
- compositions of the present invention containing purified anthocyanin as an active ingredient with a pharmaceutically effective amount, can be formulated into various forms along with pharmaceutically permitted media.
- the formulation can be prepared according to the methods notified in the field.
- the formulations whose active ingredients can be directly applied into local surface of skin include usual external preparations selected from the group consisting of ointment, gel, liquid (suspending agent, emulsion, lotion, etc.), cataplasm, tape, aerosol, powder, or dressing product, but they are not restricted by these examples. These formulations are described in the prescription paper, which is generally notified in pharmaceutical chemistry [Remington's Pharmaceutical Science, 15th Edition, 1975, Mack Publishing Company, Easton, Pennsylvania 18042 (Chapter 87: Blaug, Seymour) ] . Also, the external preparation according to the present invention can be used after being adhered onto solid supports such as the release cover of the usual band aids.
- the said dressing product provides damaged region with wet environment and helps the rapid recovery. There are closed and open dressing products. Most of them are the closed type such as film, foam, hydrocolloid, hydrogel, alginate, and collagen dressing products.
- the pharmaceutically permitted media for the external preparation of the present invention are different depending on their formulations, but the examples are hydrocarbons such as Vaseline, liquid paraffin, and gelatinized hydrocarbon
- plastibase animal or vegetable oils such as medium-chain triglyceride, lard, hard fat, and cacao butter; higher fatty acids such as cetanol, stearoyl alcohol, steric acid, isopropyl palmitate; fatty acids and their esters; water-soluble bases such as polyethylene glycol, 1,3- butyleneglycol, glycerol, gelatin, sucrose, and sugar alcohol; emulsifiers such as glycerin esters of fatty acids, polyoxyl stearate, and polyoxyethylene hydrogenated castor oil; pressure sensitive adhesives such as acrylate ester and sodium alginate; propellants such as liquefied petroleum gas and carbon dioxide; preservatives such as p-hydroxybenzoate ester.
- animal or vegetable oils such as medium-chain triglyceride, lard, hard fat, and cacao butter
- higher fatty acids such as cetanol, stearoyl alcohol, steric acid, isopropyl palmitate
- the external preparation of the present invention can be made using them according to the usual method. Also, other than these agents, stabilizers, perfumes, colorants, pH adjusters, diluents, surfactants, preservatives, antioxidants, etc. may be compounded if necessary.
- the external preparation of the present invention is applied on local wound regions according to the usual method.
- ointment cream, gel, and lotion
- bases such as white Vaseline, yellow Vaseline, lanolin, white beeswax, cetyl alcohol, stearyl alcohol, stearic acid, hydrogenated oil, hydrocarbon gel, polyethylene glycol, liquid paraffin, squalene; solvents and solubilizing agents such as oleic acid, isopropyl myristate, glyceryl triisooctanoate, crotamiton, diethyl sebacate, diisopropyl adipate, hexyl laurate, fatty acid, fatty acid ester, aliphatic alcohol, and vegetable oil; antioxidants such as tocopherol derivatives, L-ascorbic acid, dibutyl hydroxy toluene, and butylated hydroxyanisol; antiseptics such as p-hydroxybenzoate; moisturizers such as glycerin, propylene glycol
- tackifiers such as polyacrylic acid and polyacrylic acid copolymer
- crosslinking agents such as aluminium sulfate, aluminium potassium sulfate, aluminium chloride, magnesium aluminometasilicate, and dihydroxy aluminium acetate
- thickeners such as sodium polyacrylate, polyvinyl alcohol, polyvinyl pyrrolidone, gelatin, sodium alginate, carboxymethyl cellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose
- polyhydric alcohols such as glycerin, polyethylene glycol (macrogol) , propylene glycol, 1, 3-butandiol
- surfactants such as polyoxyethylene derivatives
- perfumes such as 1-menthol
- antiseptics such as p-hydroxybenzoate
- purified water and other suitable additives.
- aqueous tapes can be prepared with polymer that can contain water such as sodium polyacrylate or polyvinyl alcohol and a little amount of purified water.
- excipients such as potato starch, rice starch, corn starch, talc, zinc oxide, and other suitable additives.
- aerosols there could be compounds, as in ointment, cream, gel, suspending agent, emulsion, liquid, lotion, and external powder, containing the followings: bases such as white Vaseline, yellow Vaseline, lanolin, white beeswax, cetyl alcohol, stearyl alcohol, stearic acid, hydrogenated oil, hydrocarbon gel, polyethylene glycol, liquid paraffin, squalene; solvents and solubilizing agents such as oleic acid, isopropyl myristate, diisopropyl adipate, diisopropyl sebacate, glyceryl triisooctanoate, crotamiton, diethyl sebacate, hexyl laurate, fatty acid, fatty acid ester, aliphatic alcohol, and vegetable oil;
- the external preparation of the present invention is made using the usual preparation method such as mixing each component and necessary materials and used by the usual methods including a direct application on the injury or use by being coated or impregnated on clothes.
- the ingredients are fat, fat oil, lanolin, beeswax, resin, plastic, glycols, higher alcohol, glycerin, water, emulsifier, suspending agent, and other suitable additives.
- the active ingredient is added and mixed to make the whole uniform.
- additives such as absorption enhancers, antioxidants, antiseptics, surfactants, purified water, etc. are added if necessary, and then micro powder of the active ingredient is also added and mixed to obtain the ointment or cream.
- oleaginous ointments for instance, ingredients are melted with heat and then mixed and half cooled.
- the active ingredient other than the bases is liquefied or micropowered to get mixed with some part of the bases.
- the rest of the bases are added and stirred for uniformity.
- emulsion ointments and aqueous ointments for instance, solid bases are melted in a water bath and kept at 75 ° C Then, the aqueous bases are dissolved in water and those heated at the same or slightly higher temperature are added, and then mixed for uniformity.
- the active ingredient is mixed in advance with ointments having an aqueous polymer that has abundant water retention such as gelatin, carmellose sodium, methylcellulose, sodium polyacrylate, etc., and applied thinly on the support such as non woven fabrics.
- ointments having an aqueous polymer that has abundant water retention such as gelatin, carmellose sodium, methylcellulose, sodium polyacrylate, etc.
- plastic film such as polyethylene or polypropylene
- styrene-isoprene-styrene block copolymers or pressure sensitive adhesive such as acryl resins are added with tackifiers such as alicylic saturated hydrocarbon type resins, rosin resins, and terpenoid resins, softners such as liquid rubber and liquid paraffin, absorption enhancers, antioxidants, etc.
- tackifiers such as alicylic saturated hydrocarbon type resins, rosin resins, and terpenoid resins, softners such as liquid rubber and liquid paraffin, absorption enhancers, antioxidants, etc.
- organic solvents such as toluene and stirred or melted with heat.
- the active ingredient on the liquid or powder state is added and mixed, which is then thinly applied on the release paper. In case of dissolved one, it is thinly applied on the paper and dried, and then layered on flexible supports such as polyurethane film, polyethylene film, polyvinyl chloride film, woven fabrics, and non woven fabrics and cut for
- the active ingredient, solvents, softners, suspending agents are added into aqueous liquid to make it uniform.
- the suspending lotion makes the active ingredient refined and glycerin or ethanol makes it easy to be wet in water.
- the suspending solution or lotion is slowly added to soften and make it uniform.
- emulsion lotions an oil-soluble agent and oil phase are put into one container and water phase into another, and then they are heated respectively.
- oil phase is slowly injected into water phase.
- water phase is slowly injected into oil phase and mixed until it obtains the complete emulsification and becomes uniformed liquid.
- the active ingredient and additives are uniformly dispersed into excipients such as potato starch, rice starch, corn starch, talc, zinc oxide, etc.
- the skin wounds causing pain which is the treatment object of the external preparation of the present invention, are temperature injuries such as burn, combustion, combustion ulceration, frostbite; traumas such as laceration, abrasion, incised wound, punctured wound, acne, and bite; blood and lymphatic vessel injuries such as Buerger's disease, lymphedema, and ulcus cruris; after-surgery wounds such as wounds from skin graft and sutured wounds; decubitus ulcer, pressure ulceration, diabetic ulcer and necrosis, postherpetic ulceration, drug-induced ulceration, stoma, irradiation injury, chemical injury and other skin wounds.
- temperature injuries such as burn, combustion, combustion ulceration, frostbite
- traumas such as laceration, abrasion, incised wound, punctured wound, acne, and bite
- blood and lymphatic vessel injuries such as Buerger's disease, lymphedema, and ulcus cruris
- the pharmaceutically effective amount of anthocyanin which is used for the pharmaceutical compositions of the present invention for wound treatment, means the amount of the active ingredient that shows the treatment effect by normalizing abnormal cells and various cell activating materials in wounded parts.
- the effective dose may change depending on patients' wound type, applied part, number of treatment, treatment period, formulation, patients' state, assisting agent type, etc.
- the amount of anthocyanin contained in the external preparation is different depending on formulations, but the effective dose is 0.01-50 weight% to the whole weight of the preparation, or desirably 0.1-10 weight%. When the amount of anthocyanin is less than 0.01 weight%, wound treatment actions are not exhibited well enough and when it is more than 50 weight%, it is hard to prescribe the preparation.
- the number of dosage can be 3-4 times a day to once a week.
- Figure 1 is the picture showing full-thickness skin wounds of the control group and the experimental group in
- Experimental Example 1 (a) wound design of the control group and the experimental group; (b) wounds of the control group and the experimental group) .
- Figure 2 is the picture showing the result in vivo in Experimental Example 1 (21 days after the wounds) .
- Figure 3 is the graph displaying the comparison of wound treatment between the control group and the experimental group in Experimental Example 1.
- Example 1 Extraction and Purification of Anthocyanin Using 200 g of black soybean seed coats (Glycine max (L) Merr.) cropped in the farmland of Gyeongsang National University at Jinju, it was extracted by methanol at 4 ° C for 24 hours, which was repeated three times. The extraction was concentrated under reduced pressure and diluted until its volume reached 200ml. The solution containing anthocyanin was concentrated to be 100 ml and purified using Amberlite XAD-7 column and Spephadex LH-20. The purified anthocyanin was then composed of 72% of cyanidin-3-glucoside, 20% of cyanidin-3- glucoside, and 6% of petunidin-3-glucoside.
- Figure 3 shows the degree of treatment effect after measuring the unhealed wound section.
- the unhealed wound section was 49.3 %, which means the half of the initial wound section was cured. 14 days after the coating, 79% of the wound section was healed and 21 days after the coating, 95% was healed. On the contrary, when only physiological saline solution was coated, it showed 32% of healed section after 7 days, 57% after 14, and 78% after 21.
- compositions of the present invention for wound healing containing anthocyanin as an active ingredient, which is extracted from black soybeans, especially black soybean seed coats, and composed of 65 ⁇ 80 weight% of cyanidin-3-glucoside, 15 ⁇ 25 weight% of delphinidin-3-glucoside, and 5-10 weight% of petunidin-3-glucoside, shows the excellent effect on wound treatment, so it can be used as a great wound healing agent.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to pharmaceutical compositions for wound healing, containing anthocyanin as an active ingredient, which is extracted from black soybeans, especially black soybean seed coats. More specifically, the anthocyanin is composed of cyanidin-3-glucoside, delphinidin- 3-glucoside, and petunidin-3-glucoside.
Description
Pharmaceutical composition for wound healing containing anthocyanin extracted from the black soybean seed coat
[Technical Field] The present invention relates to pharmaceutical compositions for wound healing, containing anthocyanin as an active ingredient, which is extracted from black soybeans, especially black soybean seed coats. More specifically, the anthocyanin is composed of cyanidin-3-glucoside, delphinidin- 3-glucoside, and petunidin-3-glucoside.
[Background Art]
Anthocyanin is a water-soluble pigment glucoside, which exists in flowers, fruits, stems, leaves, and roots of plants. It is usually found in vacuoles of plants and it is a natural dye representing colors such as violet, red, and blue according to the acidity of cell sap, the chemical structure of dye compounds, and binding status with other metal ions. Anthocyanin is composed of aglycone and glycoside. Currently the anthocyanin component is extracted from such plants as grapes, strawberries, olives, red cabbages, eggplants, roses, etc. and used as various materials. Yet, in fact, it is extracted and used almost as a co-pigment and often used with the compounds of other ingredients.
Anthocyanin, a natural vegetable dye, has recently been known to have some bioactivities . The well-known examples are anti-aging and antibacterial effect, anti-mutagenicity, cholesterol decrease, eyesight improvement, blood vessel protection, anti-ulcerative, and antioxidant effect. These bioactivities are basic for every kind of anthocyanin, but it was recently found that each anthocyanin has slightly different bioactivities.
It is known that anthocyanin is easily absorbed in intestines and it was also reported that its powerful antioxidant effect showed the protection ability for cells and tissues in animal models, in case of the ischemic infarction in the liver and heart and the acute inflammation in the lung (Takanori Tsuda et al., Archives of Biochemistry and Biophysics, 1999, 368 (2) : 361-366; Amorini A.M. et al, Free Radic. Res. 2003, 37 (4 ): 453-460) . Also, in Korean Laid-Open Patent Publication No. 2007-0026284, it is disclosed as a therapeutic agent that can protect the brain cell injury resulted from the stroke due to the complexity of the mechanism of brain injury.
A wound means an injured part of a body, including pathologically cut or damaged tissues in internal or external surface such as muscles, nervous tissues, bones, soft tissues,
internal organs, and vascular tissues. The examples are contusion, noncurative traumatic wound, tissue destruction by irradiation, abrasion, osteonecrosis, laceration, avulsion, penetrated wound, gun shot wound, incised wound, burn, frostbite, skin ulcer, xeroderma, palmoplantar keratoderma, rough and cracked skin, dermatitis, pain from dermatophytosis, operation wound, vascular disorder wound, cornea wound, decubitus ulcer, bedsore, diabetic and poor circulation related state such as diabetic skin erosion, chronic ulcer, stitched part after plastic surgery, spinal cord injury wound, gynaecological wound, chemical wound, and acne. The examples are not restricted by these and they also include some partial injuries .
Several therapeutic agents have been developed for wounds. Most of them have the granulation tissue proliferation action and the medication at the initial phase of burn may worse the symptoms. Also, regarding wound remedies containing iodine, there have been reports that they caused hypersensitiveness and delayed the cure due to cytotoxicity of iodine. Yet, there have been no examples found that anthocyanin could be used to treat wounds.
On the other hand, there have been many studies on black soybeans since the Food and Drug Administration approved that
the soy protein helps prevent the coronary heart disease in 1998. It is known that black soybeans contain essential fatty acids, lecithin, fiber, saponin, etc., so that they have the effect to prevent and treat adult diseases such as hypertension, diabetes, arteriosclerosis, and obesity. The vegetable fiber contained in black soybeans is known to have the effect to prevent not only constipation but also colon cancer. Donguibogam, the Korean medical book written in the 17th century, describes black soybeans as "a drug that protects the five viscera, keeps intestines warm by helping twelve meridians, gets rid of boils, and treats radiating pain".
Also, anthocyanin, a pigment contained in black soybeans, has the anti-aging effect in case of a constant use as antioxidants. Isoflavone, the soy protein, contains saponin and phytosterol as well as genistin that have powerful anticancer activities, and helps calcium absorption into bones. Particularly, the seed coats of black soybeans contain an anticancer material called glycitein.
Anthocyanin is a water-soluble pigment glucoside and largely divided into six kinds of anthocyanidins depending on the number of the hydroxyl groups and the methylation of specific hydroxyl groups. It is also divided into hundreds of kinds depending on the sort of sugar, which is bonded with anthocyanidins, and the sort and bonding location of the acyl
group.
[Disclosure of Invention] [Technical Subject] While conducting the study on wound treatment, the present inventors found to their surprises that anthocyanin extracted from black soybeans, especially from their seed coats was effective for treating wounds. It was also found that the damaged skin was rapidly cured or recovered when the agent containing the said purified anthocyanin as an active ingredient was applied on the wound, and the present invention was completed.
Therefore, the object of the present invention is to provide the pharmaceutical compositions containing anthocyanin extracted from black soybean seed coats to treat wounds.
[Technical Solution]
The present invention relates to pharmaceutical compositions for wound healing, containing anthocyanin as an active ingredient, which is extracted from black soybeans, especially black soybean seed coats. More specifically, the anthocyanin is composed of cyanidin-3-glucoside, delphinidin- 3-glucoside, and petunidin-3-glucoside .
The purified anthocyanin of the present invention is composed of 65-80 weight% of cyanidin-3-glucoside, 15-25 weight% of delphinidin-3-glucoside, and 5-10 weight% of petunidin-3-glucoside.
The pharmaceutical compositions of the present invention, containing purified anthocyanin as an active ingredient with a pharmaceutically effective amount, can be formulated into various forms along with pharmaceutically permitted media. The formulation can be prepared according to the methods notified in the field.
The formulations whose active ingredients can be directly applied into local surface of skin include usual external preparations selected from the group consisting of ointment, gel, liquid (suspending agent, emulsion, lotion, etc.), cataplasm, tape, aerosol, powder, or dressing product, but they are not restricted by these examples. These formulations are described in the prescription paper, which is generally notified in pharmaceutical chemistry [Remington's Pharmaceutical Science, 15th Edition, 1975, Mack Publishing Company, Easton, Pennsylvania 18042 (Chapter 87: Blaug, Seymour) ] . Also, the external preparation according to the present invention can be used after being adhered onto solid supports such as the release cover of the usual band aids. The
said dressing product provides damaged region with wet environment and helps the rapid recovery. There are closed and open dressing products. Most of them are the closed type such as film, foam, hydrocolloid, hydrogel, alginate, and collagen dressing products.
The pharmaceutically permitted media for the external preparation of the present invention are different depending on their formulations, but the examples are hydrocarbons such as Vaseline, liquid paraffin, and gelatinized hydrocarbon
(also known as plastibase) ; animal or vegetable oils such as medium-chain triglyceride, lard, hard fat, and cacao butter; higher fatty acids such as cetanol, stearoyl alcohol, steric acid, isopropyl palmitate; fatty acids and their esters; water-soluble bases such as polyethylene glycol, 1,3- butyleneglycol, glycerol, gelatin, sucrose, and sugar alcohol; emulsifiers such as glycerin esters of fatty acids, polyoxyl stearate, and polyoxyethylene hydrogenated castor oil; pressure sensitive adhesives such as acrylate ester and sodium alginate; propellants such as liquefied petroleum gas and carbon dioxide; preservatives such as p-hydroxybenzoate ester. The external preparation of the present invention can be made using them according to the usual method. Also, other than these agents, stabilizers, perfumes, colorants, pH adjusters,
diluents, surfactants, preservatives, antioxidants, etc. may be compounded if necessary.
The external preparation of the present invention is applied on local wound regions according to the usual method.
In case of the ointment, cream, gel, and lotion, there could be compounds containing bases such as white Vaseline, yellow Vaseline, lanolin, white beeswax, cetyl alcohol, stearyl alcohol, stearic acid, hydrogenated oil, hydrocarbon gel, polyethylene glycol, liquid paraffin, squalene; solvents and solubilizing agents such as oleic acid, isopropyl myristate, glyceryl triisooctanoate, crotamiton, diethyl sebacate, diisopropyl adipate, hexyl laurate, fatty acid, fatty acid ester, aliphatic alcohol, and vegetable oil; antioxidants such as tocopherol derivatives, L-ascorbic acid, dibutyl hydroxy toluene, and butylated hydroxyanisol; antiseptics such as p-hydroxybenzoate; moisturizers such as glycerin, propylene glycol, sodium hyaluronate; surfactants such as polyoxyethylene derivative, glycerol ester of fatty acids, sucrose ester of fatty acids, sorbitan ester of fatty acids, propylene glycol ester of fatty acids, and lecithin; thickeners such as carboxy vinyl polymer, xanthan gum, carboxymethyl cellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose;
propellants such as liquefied petroleum gas, liquefied carbon dioxide, dimethylether, nitrogen, kerosene, and carbon dioxide; stabilizers; preservatives; absorption enhancers; and other suitable additives. For cataplasms, there are compounds containing tackifiers such as polyacrylic acid and polyacrylic acid copolymer; crosslinking agents such as aluminium sulfate, aluminium potassium sulfate, aluminium chloride, magnesium aluminometasilicate, and dihydroxy aluminium acetate; thickeners such as sodium polyacrylate, polyvinyl alcohol, polyvinyl pyrrolidone, gelatin, sodium alginate, carboxymethyl cellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose; polyhydric alcohols such as glycerin, polyethylene glycol (macrogol) , propylene glycol, 1, 3-butandiol; surfactants such as polyoxyethylene derivatives; perfumes such as 1-menthol; antiseptics such as p-hydroxybenzoate; purified water; and other suitable additives.
For tapes, there are compounds containing pressure sensitive adhesives such as styrene-isoprene-styrene block copolymer and acryl resin; tackifiers such as alicylic saturated hydrocarbon type resin, rosin resin, and terpenoid resin; softners such as liquid rubber, liquid paraffin; antioxidants such as dibutyl hydroxy toluene; polyhydric
alcohols such as propylene glycol; absorption enhancers such as oleic acid, surfactants such as polyoxyethylene derivatives; and other suitable additives. Also, aqueous tapes can be prepared with polymer that can contain water such as sodium polyacrylate or polyvinyl alcohol and a little amount of purified water.
For powder, there are compounds containing excipients such as potato starch, rice starch, corn starch, talc, zinc oxide, and other suitable additives. For aerosols, there could be compounds, as in ointment, cream, gel, suspending agent, emulsion, liquid, lotion, and external powder, containing the followings: bases such as white Vaseline, yellow Vaseline, lanolin, white beeswax, cetyl alcohol, stearyl alcohol, stearic acid, hydrogenated oil, hydrocarbon gel, polyethylene glycol, liquid paraffin, squalene; solvents and solubilizing agents such as oleic acid, isopropyl myristate, diisopropyl adipate, diisopropyl sebacate, glyceryl triisooctanoate, crotamiton, diethyl sebacate, hexyl laurate, fatty acid, fatty acid ester, aliphatic alcohol, and vegetable oil; antioxidants such as tocopherol derivatives, L- ascorbic acid, dibutyl hydroxy toluene, and butylated hydroxyanisol; antiseptics such as p-hydroxybenzoate; moisturizers such as glycerin, propylene glycol, sodium hyaluronate; surfactants such as polyoxyethylene derivative,
glycerol ester of fatty acids, sucrose ester of fatty acids, sorbitan ester of fatty acids, propylene glycol of fatty acids, and lecithin; thickeners such as carboxyvinyl polymer, xanthan gum, carboxymethyl cellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose; excipients such as potato starch, rice starch, corn starch, talc, and zinc oxide; propellants such as liquefied petroleum gas, liquefied carbon dioxide, dimethylether, nitrogen, kerosene, and carbon dioxide; buffers; correctives; suspending agents; emulsifiers; flavoring agents; preservatives, solubilizing agents; and other suitable additives.
The external preparation of the present invention is made using the usual preparation method such as mixing each component and necessary materials and used by the usual methods including a direct application on the injury or use by being coated or impregnated on clothes.
To prepare ointments, the ingredients are fat, fat oil, lanolin, beeswax, resin, plastic, glycols, higher alcohol, glycerin, water, emulsifier, suspending agent, and other suitable additives. Or using these as bases, the active ingredient is added and mixed to make the whole uniform. After the base components are melted with heat and mixed uniformly, additives such as absorption enhancers, antioxidants,
antiseptics, surfactants, purified water, etc. are added if necessary, and then micro powder of the active ingredient is also added and mixed to obtain the ointment or cream.
To prepare oleaginous ointments, for instance, ingredients are melted with heat and then mixed and half cooled. The active ingredient other than the bases is liquefied or micropowered to get mixed with some part of the bases. Then the rest of the bases are added and stirred for uniformity. To prepare emulsion ointments and aqueous ointments, for instance, solid bases are melted in a water bath and kept at 75°C Then, the aqueous bases are dissolved in water and those heated at the same or slightly higher temperature are added, and then mixed for uniformity. To prepare cataplams, the active ingredient is mixed in advance with ointments having an aqueous polymer that has abundant water retention such as gelatin, carmellose sodium, methylcellulose, sodium polyacrylate, etc., and applied thinly on the support such as non woven fabrics. After the surface of the base is coated with plastic film such as polyethylene or polypropylene, it is cut for a desired size.
To prepare tapes, styrene-isoprene-styrene block copolymers or pressure sensitive adhesive such as acryl resins are added with tackifiers such as alicylic saturated
hydrocarbon type resins, rosin resins, and terpenoid resins, softners such as liquid rubber and liquid paraffin, absorption enhancers, antioxidants, etc. This mixture is dissolved in organic solvents such as toluene and stirred or melted with heat. Into the stirred compound, the active ingredient on the liquid or powder state is added and mixed, which is then thinly applied on the release paper. In case of dissolved one, it is thinly applied on the paper and dried, and then layered on flexible supports such as polyurethane film, polyethylene film, polyvinyl chloride film, woven fabrics, and non woven fabrics and cut for a desired size.
To prepare lotions, the active ingredient, solvents, softners, suspending agents are added into aqueous liquid to make it uniform. The suspending lotion makes the active ingredient refined and glycerin or ethanol makes it easy to be wet in water. Then the suspending solution or lotion is slowly added to soften and make it uniform. For emulsion lotions, an oil-soluble agent and oil phase are put into one container and water phase into another, and then they are heated respectively. For the 0/W type emulsion, oil phase is slowly injected into water phase. For the W/0 type, on the contrary, water phase is slowly injected into oil phase and mixed until it obtains the complete emulsification and becomes uniformed liquid.
To prepare powder, the active ingredient and additives are uniformly dispersed into excipients such as potato starch, rice starch, corn starch, talc, zinc oxide, etc.
To prepare aerosols, after the solvent containing the active ingredient, ointment, cream, gel, suspending agent, emulsion, liquid, lotion, external preparations, etc. is made according to the said method, they are charged in a closed container with liquefied petroleum gas or compressed gas.
The skin wounds causing pain, which is the treatment object of the external preparation of the present invention, are temperature injuries such as burn, combustion, combustion ulceration, frostbite; traumas such as laceration, abrasion, incised wound, punctured wound, acne, and bite; blood and lymphatic vessel injuries such as Buerger's disease, lymphedema, and ulcus cruris; after-surgery wounds such as wounds from skin graft and sutured wounds; decubitus ulcer, pressure ulceration, diabetic ulcer and necrosis, postherpetic ulceration, drug-induced ulceration, stoma, irradiation injury, chemical injury and other skin wounds.
The pharmaceutically effective amount of anthocyanin, which is used for the pharmaceutical compositions of the present invention for wound treatment, means the amount of the active ingredient that shows the treatment effect by
normalizing abnormal cells and various cell activating materials in wounded parts. The effective dose may change depending on patients' wound type, applied part, number of treatment, treatment period, formulation, patients' state, assisting agent type, etc.
The amount of anthocyanin contained in the external preparation is different depending on formulations, but the effective dose is 0.01-50 weight% to the whole weight of the preparation, or desirably 0.1-10 weight%. When the amount of anthocyanin is less than 0.01 weight%, wound treatment actions are not exhibited well enough and when it is more than 50 weight%, it is hard to prescribe the preparation. The number of dosage can be 3-4 times a day to once a week.
[Brief Description of Drawings]
Figure 1 is the picture showing full-thickness skin wounds of the control group and the experimental group in
Experimental Example 1 ( (a) wound design of the control group and the experimental group; (b) wounds of the control group and the experimental group) .
Figure 2 is the picture showing the result in vivo in Experimental Example 1 (21 days after the wounds) .
Figure 3 is the graph displaying the comparison of wound
treatment between the control group and the experimental group in Experimental Example 1.
[Best Mode for Carrying Out the Invention] Hereinafter, the present invention is described in more detail based on the following examples. But, these examples are not intended to limit the scope of the present invention.
[Example 1] Extraction and Purification of Anthocyanin Using 200 g of black soybean seed coats (Glycine max (L) Merr.) cropped in the farmland of Gyeongsang National University at Jinju, it was extracted by methanol at 4 °C for 24 hours, which was repeated three times. The extraction was concentrated under reduced pressure and diluted until its volume reached 200ml. The solution containing anthocyanin was concentrated to be 100 ml and purified using Amberlite XAD-7 column and Spephadex LH-20. The purified anthocyanin was then composed of 72% of cyanidin-3-glucoside, 20% of cyanidin-3- glucoside, and 6% of petunidin-3-glucoside.
[Experimental Example 1] Comparing wound treatment effects according to anthocyanin and physiological saline solution
To find out the wound treatment effect of anthocyanin, the experiment was conducted as below. The hair on the back of
15 rats for experiments (Sprague-Dawley rat) was shaved and the skin above the panniculus carnosus layer was eliminated to make two symmetrical squares with a 2x2 cm size (as in Figure 1) . The wound on the left, the control group, was coated with the physiological saline solution and that on the right, the experimental group, with the anthocyanin solution (the λANT' solution hereafter) , in which anthocyanin of Example 1 was dissolved in distilled water to be 50mg/ml. On the wound (2cm x 2 cm), 0.1 ml of the ANT solution was coated at a time once a day. The treatment progress was observed by measuring the section of the wounds 7 days, 14 days, and 21 days after the coating. Figure 2 and 3 show the result.
As shown in Figure 2, three weeks after the ANT solution containing anthocyanin according to the present invention was coated on the rats, it had better treatment effect than physiological saline solution.
Also, Figure 3 shows the degree of treatment effect after measuring the unhealed wound section. As shown in Figure 3, 7 days after the ANT solution was coated, the unhealed wound section was 49.3 %, which means the half of the initial wound section was cured. 14 days after the coating, 79% of the wound section was healed and 21 days after the coating, 95% was healed. On the contrary, when only physiological saline
solution was coated, it showed 32% of healed section after 7 days, 57% after 14, and 78% after 21.
[industrial Applicability] The pharmaceutical compositions of the present invention for wound healing, containing anthocyanin as an active ingredient, which is extracted from black soybeans, especially black soybean seed coats, and composed of 65~80 weight% of cyanidin-3-glucoside, 15~25 weight% of delphinidin-3-glucoside, and 5-10 weight% of petunidin-3-glucoside, shows the excellent effect on wound treatment, so it can be used as a great wound healing agent.
Claims
[CLAIMS]
[Claim l]
Pharmaceutical compositions for wound healing, containing anthocyanin as an active ingredient, which is extracted from black soybeans.
[Claim 2]
The pharmaceutical compositions for wound healing of claim 1, wherein said anthocyanin is extracted from black soybean seed coats.
[Claim 3]
The pharmaceutical compositions for wound healing of claim 2, wherein said anthocyanin is composed of cyanidin-3-glucoside, delphinidin-3-glucoside, and petunidin-3-glucoside .
[Claim 4]
The pharmaceutical compositions for wound healing of claim 3, wherein said anthocyanin is composed of 65-80 weight% of cyanidin-3-glucoside, 15-25 weight% of delphinidin-3-glucoside, and 5-10 weight% of petunidin-3-glucoside.
[Claim 5] The pharmaceutical compositions for wound healing of any one of claims 1 to 4, wherein said compositions have the formulations selected from the group consisting of ointment, ointment adhesive, gel, liquid, cataplasm, tape, aerosol, powder, or dressing product.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070035372A KR100832240B1 (en) | 2007-04-11 | 2007-04-11 | Pharmaceutical composition for wound treatment containing anthocyanin extracted from black soybean hull |
KR10-2007-0035372 | 2007-04-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008126980A1 true WO2008126980A1 (en) | 2008-10-23 |
Family
ID=39665183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2008/000513 WO2008126980A1 (en) | 2007-04-11 | 2008-01-28 | Pharmaceutical composition for wound healing containing anthocyanin extracted from the black soybean seed coat |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR100832240B1 (en) |
WO (1) | WO2008126980A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011048479A3 (en) * | 2009-10-21 | 2011-08-11 | Maqui New Life S.A. | Compositions that include anthocyanidins and methods of use |
WO2014179318A2 (en) * | 2013-05-01 | 2014-11-06 | Johnson Lanny Leo | Antimicrobials and methods of use thereof for wound healing |
CN105106882A (en) * | 2015-08-18 | 2015-12-02 | 李际涛 | Traditional Chinese medicine composition for treating frostbite |
US10004705B2 (en) | 2013-05-01 | 2018-06-26 | Lanny Leo Johnson | Antimicrobials and methods of use thereof |
US10398664B2 (en) | 2013-05-01 | 2019-09-03 | Lanny Leo Johnson | Methods of diagnosing and treating infected implants |
CN113230409A (en) * | 2020-12-28 | 2021-08-10 | 上海奥茵特生物科技有限公司 | Traditional Chinese medicine composite matrix ointment for promoting wound healing |
CN115612182A (en) * | 2022-11-07 | 2023-01-17 | 广西民族大学 | CMC/starch/ZnO/anthocyanin intelligent active packaging film and preparation method thereof |
IT202200024417A1 (en) | 2022-11-25 | 2024-05-25 | Fondazione St Italiano Tecnologia | SPRAY PATCH COMPOSITION, PROCEDURE FOR ITS PRODUCTION AND KIT |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101220494B1 (en) | 2010-10-11 | 2013-01-10 | 강원대학교산학협력단 | Cosmetic Composition for Skin Whitening Comprising Liriope Seed Extracts |
KR101838142B1 (en) * | 2017-04-12 | 2018-03-14 | 한국과학기술연구원 | Composition for prevention or treatment of corneal diseases comprising small black soybean extract |
EP3946402A1 (en) * | 2019-03-29 | 2022-02-09 | Evonik Operations GmbH | Preparations containing berry extracts for use in the prophylaxis and/or treatment of viral infections caused by herpesviridae |
CN110237295B (en) * | 2019-07-29 | 2021-08-24 | 健诺维(成都)生物科技有限公司 | Anthocyanin alginate dressing |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6194469B1 (en) * | 1998-12-11 | 2001-02-27 | Board Of Trustees Operating Michigan State Univeristy | Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids |
US6656914B2 (en) * | 2000-01-28 | 2003-12-02 | Board Of Trustees Of Michigan State University | Method for treating tumors caused by APC gene mutation with anthocyanins and cyanidin |
JP2004091472A (en) * | 2002-07-09 | 2004-03-25 | National Agriculture & Bio-Oriented Research Organization | Apoptosis-inducing substances, potato foods and processed products contained in potato anthocyanins |
JP2006151922A (en) * | 2004-12-01 | 2006-06-15 | Meiji Seika Kaisha Ltd | Absorption accelerator for anthocyanin |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100379021B1 (en) * | 2000-02-28 | 2003-04-08 | 대한민국 | Method for isolation of high purity natural anthocyanin pigments from a seed coat |
MXPA04006502A (en) | 2002-01-04 | 2005-02-24 | Univ Guelph | Compositions for the preservation of fruits and vegetables. |
-
2007
- 2007-04-11 KR KR1020070035372A patent/KR100832240B1/en not_active IP Right Cessation
-
2008
- 2008-01-28 WO PCT/KR2008/000513 patent/WO2008126980A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6194469B1 (en) * | 1998-12-11 | 2001-02-27 | Board Of Trustees Operating Michigan State Univeristy | Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids |
US6656914B2 (en) * | 2000-01-28 | 2003-12-02 | Board Of Trustees Of Michigan State University | Method for treating tumors caused by APC gene mutation with anthocyanins and cyanidin |
JP2004091472A (en) * | 2002-07-09 | 2004-03-25 | National Agriculture & Bio-Oriented Research Organization | Apoptosis-inducing substances, potato foods and processed products contained in potato anthocyanins |
JP2006151922A (en) * | 2004-12-01 | 2006-06-15 | Meiji Seika Kaisha Ltd | Absorption accelerator for anthocyanin |
Non-Patent Citations (1)
Title |
---|
HYE JUNG KIM ET AL.: "Anthocyanins from soybean seed coat inhibit the expression of TNF-alpha-induced genes associated with ischemia/reperfusion in endothelial cell by NF-kappaB-dependent pathway and reduce rat myocardial damages incurred by ischemia and reperfusion in vivo", FEBS LETTERS, vol. 580, no. 5, 20 February 2006 (2006-02-20), pages 1391 - 1397, XP005289545 * |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011048479A3 (en) * | 2009-10-21 | 2011-08-11 | Maqui New Life S.A. | Compositions that include anthocyanidins and methods of use |
US10786522B2 (en) | 2009-10-21 | 2020-09-29 | Maqui NewLife S.A. | Compositions that include anthocyanidins and methods of use |
US10016380B2 (en) | 2013-05-01 | 2018-07-10 | Lanny Leo Johnson | Antimicrobials and methods of use thereof |
US10265285B2 (en) | 2013-05-01 | 2019-04-23 | Lanny Leo Johnson | Antimicrobials and methods of use thereof |
US11103471B2 (en) | 2013-05-01 | 2021-08-31 | Lanny Leo Johnson | Antimicrobials and methods of use thereof |
US9498413B2 (en) | 2013-05-01 | 2016-11-22 | Lanny Leo Johnson | Antimicrobials and methods of use thereof for wound healing |
US20160361273A1 (en) * | 2013-05-01 | 2016-12-15 | Lanny Leo Johnson | Antimicrobials and methods of use thereof for wound healing |
US9925152B2 (en) | 2013-05-01 | 2018-03-27 | Lanny Leo Johnson | Antimicrobials and methods of use thereof for wound healing |
US10004705B2 (en) | 2013-05-01 | 2018-06-26 | Lanny Leo Johnson | Antimicrobials and methods of use thereof |
US10004706B2 (en) | 2013-05-01 | 2018-06-26 | Lanny Leo Johnson | Antimicrobials and methods of use thereof |
US20140328902A1 (en) * | 2013-05-01 | 2014-11-06 | Lanny Leo Johnson | Antimicrobials and methods of use thereof for wound healing |
US10034842B2 (en) | 2013-05-01 | 2018-07-31 | Lanny Leo Johnson | Antimicrobials and methods of use thereof for wound healing |
US10143670B2 (en) | 2013-05-01 | 2018-12-04 | Lanny Leo Johnson | Antimicrobials and methods of use thereof |
WO2014179318A3 (en) * | 2013-05-01 | 2014-12-24 | Johnson Lanny Leo | Antimicrobials and methods of use thereof for wound healing |
US10292946B2 (en) | 2013-05-01 | 2019-05-21 | Lanny Leo Johnson | Antimicrobials and methods of use thereof for wound healing |
US10398664B2 (en) | 2013-05-01 | 2019-09-03 | Lanny Leo Johnson | Methods of diagnosing and treating infected implants |
US10426747B2 (en) | 2013-05-01 | 2019-10-01 | Lanny Leo Johnson | Antimicrobials and methods of use thereof |
US10772860B2 (en) | 2013-05-01 | 2020-09-15 | Lanny Leo Johnson | Antimicrobials and methods of use thereof |
WO2014179318A2 (en) * | 2013-05-01 | 2014-11-06 | Johnson Lanny Leo | Antimicrobials and methods of use thereof for wound healing |
CN105106882A (en) * | 2015-08-18 | 2015-12-02 | 李际涛 | Traditional Chinese medicine composition for treating frostbite |
CN113230409A (en) * | 2020-12-28 | 2021-08-10 | 上海奥茵特生物科技有限公司 | Traditional Chinese medicine composite matrix ointment for promoting wound healing |
CN115612182A (en) * | 2022-11-07 | 2023-01-17 | 广西民族大学 | CMC/starch/ZnO/anthocyanin intelligent active packaging film and preparation method thereof |
IT202200024417A1 (en) | 2022-11-25 | 2024-05-25 | Fondazione St Italiano Tecnologia | SPRAY PATCH COMPOSITION, PROCEDURE FOR ITS PRODUCTION AND KIT |
Also Published As
Publication number | Publication date |
---|---|
KR100832240B1 (en) | 2008-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008126980A1 (en) | Pharmaceutical composition for wound healing containing anthocyanin extracted from the black soybean seed coat | |
KR100812596B1 (en) | Skin protection composition comprising a naturally derived compound | |
ES2206567T3 (en) | EXTERNAL PREPARATIONS FOR THE TREATMENT OF DERMATOSIS. | |
US20110250154A1 (en) | Cosmetic compositions comprising polyhydroxyltate fatty alcohols and derivatives and uses thereof | |
JPH0676335B2 (en) | Complex of Vitis vinifera extract and phospholipid, method for producing the same, pharmaceutical and cosmetics | |
MX2011003940A (en) | Process for extracting cardiac glycodides and compositions. | |
EP2575795A1 (en) | Stabilized formulation comprising omega-3 fatty acids and use of the fatty acids for skin care and/or wound care | |
US12186346B2 (en) | Topical composition comprised of cod liver oil for treating wounds and skin disorders | |
EP2763686A1 (en) | Composition for the treatment of skin lesions | |
EP2836210B1 (en) | An agent for inducing the synthesis of heat-shock proteins in human and animal cells; a cosmetic preparation for enhancing reparative processes; a cosmetic preparation for reducing side effects of aggressive cosmetic procedures; a food supplement; a foodstuff; a method of reducing side effects of aggressive cosmetic procedures | |
KR102156731B1 (en) | Bakuchiol compositions for treatment of post inflammatory hyperpigmentation | |
WO2008126979A1 (en) | Pharmaceutical composition for the prevention and treatment of the ischemia-reperfusion injury in the flaps or tissues containing anthocyanin extracted from the black soybean seed coat | |
KR20240005828A (en) | wound care composition | |
CN106456600A (en) | Treatment or prevention of seborrheic keratosis using artemisinin and derivatives thereof | |
Shaikh et al. | Traditional remedies for wound healing: a review | |
KR20050063771A (en) | External preparation for inhibiting keloid formation | |
CA2554748A1 (en) | External preparation for treating painful skin wound | |
WO2017096450A1 (en) | New compounds with antioxidant and antiaging activity | |
RU2183962C2 (en) | Composition to treat and prevent human and animal skin diseases and wounds | |
JP2008094793A (en) | Wound-related acute inflammation-curative agent | |
KR20230057788A (en) | A composition to remove or to relieve bruise | |
JP2004292341A (en) | External preparation for inhibiting formation of keloid, and the like | |
JP2004137215A (en) | External preparation for remedy of painful skin wound | |
KR20060130651A (en) | External preparations for the treatment of painful skin wounds | |
JPH02221221A (en) | External preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08712215 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08712215 Country of ref document: EP Kind code of ref document: A1 |